comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 01:02:06 - browse：6

Bernard Moss, a research scientist at NIAID. -- Infectious disease coverage from STAT — Bernard Moss Courtesy NIAID

For more than half a century, scientist Bernard Moss has been commanding the attention of peers interested in prying biological secrets from poxviruses and other microbiological targets. Now he’s commanding the attention of a different audience: House Republicans.

Moss, who will mark his 86th birthday in late July and who goes by Bernie, has worked for more than 55 years in the laboratories of the National Institute of Allergy and Infectious Diseases in Bethesda, Md. Over that time, he has been investigating viruses in relative anonymity — except, that is, among the virological cognoscenti.

But last year, in an interview with Science, Moss said he planned to try to determine why one strain of mpox viruses, known as Clade 1, is so much more virulent than those in a second strain, Clade 2, by taking genes from the former and putting them into the latter. Clade 2 viruses are responsible for the ongoing mpox outbreak first detected in May 2022.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： The untold story of TV’s first prescription drug ad

knowledge

WSS

STAT Summit: Meghan O’Rourke on making chronic illness visible

Is there really a nursing shortage in the U.S.?

Medicare drug price negotiation hearing pits pharma v Biden admin

Longer MASH drug regimen improved liver, Akero study finds

Streamlined flu vaccines recommended by FDA advisory panel

Medicare drug price negotiation continues, as pharma counteroffers

leisure time

comprehensive

focus

In Memoriam: Notable people who died in 2023

Ozempic has benefits for kidney disease as well as diabetes

As demand for Covid shots wanes, Moderna seeks its next success

For AI in health care standards, federal regulators join with industry group

Novavax promises a turnaround & Lilly roils the obesity market

Families look for replacement for GSK asthma drug Flovent

Continuity nursing helped my family in our darkest PICU moments

Results on Novartis prostate cancer therapy could expand its use

Moonlake's readout produced a cash windfall. Risks remain

ADCs take center stage as promising cancer treatments

hotspot

The problems with dementia villages

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Roche drug slashes death risk in early

STAT Summit: The economic case for universal basic health care

Roche drug slashes death risk in early

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

hotspot

knowledge

hotspot

explore